

Application No. 10/715,667
Resp to OA filed June 21, 2006
Office Action dated April 28, 2006

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-12 (canceled).

13. (currently amended). An isolated polypeptide having HPR2 polypeptide activity comprising amino acids 24-318 of SEQ ID NO:21, ~~an amino acid sequence selected from the group consisting of:~~

- (a) ~~SEQ ID NO:25;~~
- (b) ~~an amino acid sequence of SEQ ID NO:25 that is at least 50% of the length of the amino acid sequence of SEQ ID NO:25 and that comprises amino acids 349 through 356 of SEQ ID NO:25;~~
- (c) ~~an amino acid sequence sharing at least 99% amino acid identity across the entire length of the amino acid sequence of (b);~~
- (d) ~~an amino acid sequence comprising both an amino acid sequence of (b) or (c), and amino acids 216 through 245 of SEQ ID NO:16;~~
- (e) ~~an amino acid sequence of (b) or (c) comprising a fragment of SEQ ID NO:25 comprising an Ig-like domain amino acid sequence;~~
- (f) ~~an amino acid sequence of (b) or (c) comprising a fragment of SEQ ID NO:25 comprising a cytokine receptor domain amino acid sequence;~~
- (g) ~~an amino acid sequence of (b) or (c) comprising amino acids 24 through 331 of SEQ ID NO:21; and~~
- (h) ~~an amino acid sequence of (c), wherein a polypeptide comprising said amino acid sequence of (c) binds to an antibody that also binds to a polypeptide comprising an amino acid sequence of any of (a)-(b).~~

14. (currently amended). The polypeptide of claim 13 wherein the polypeptide Ig-like domain amino acid sequence comprises amino acids ~~24 30~~ through ~~629 415~~ of SEQ ID NO:21.

15. (currently amended). The polypeptide of claim ~~14 13~~ wherein the polypeptide cytokine receptor domain amino acid sequence comprises amino acids ~~1 133~~ through ~~629 309~~ of SEQ ID NO:21.

16. (currently amended). The polypeptide of claim 13 wherein the polypeptide comprises amino acids 24 through ~~348 331~~ of SEQ ID NO:21 and amino acids 349 through 356 of SEQ ID NO:25.

Application No. 10/715,667
Resp to OA filed June 21, 2006
Office Action dated April 28, 2006

17. (canceled).

18. (currently amended). The polypeptide of claim 16 ~~17~~ further comprising amino acids 1 through 348 of SEQ ID NO:21 ~~216 through 245 of SEQ ID NO:16~~.

19. (currently amended). The polypeptide of claim 13 ~~17~~ wherein the polypeptide further comprises amino acids 319 ~~24~~ through 565 ~~331~~ of SEQ ID NO:2324.

20. (currently amended). The polypeptide of claim 19 ~~17~~ wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:2325.

21. (currently amended). A polypeptide expressed by a process comprising providing an expression vector comprising a nucleotide sequence encoding an HPR2 polypeptide comprising amino acids 24-318 of SEQ ID NO:21, ~~an amino acid sequence selected from the group consisting of:~~

(a) ~~— SEQ ID NO:25;~~

(b) ~~— an amino acid sequence of SEQ ID NO:25 that is at least 50% of the length of the amino acid sequence of SEQ ID NO:25 and that comprises amino acids 349 through 356 of SEQ ID NO:25;~~

(c) ~~— an amino acid sequence sharing at least 90% amino acid identity across the entire length of the amino acid sequence of (b);~~

(d) ~~— an amino acid sequence comprising both an amino acid sequence of (b) or (c), and amino acids 216 through 245 of SEQ ID NO:16;~~

(e) ~~— an amino acid sequence of (b) or (c) comprising amino acids 30 through 115 of SEQ ID NO:21;~~

(f) ~~— an amino acid sequence of (b) or (c) comprising amino acids 133 through 309 of SEQ ID NO:21; and~~

(g) ~~— an amino acid sequence of (b) or (c) comprising amino acids 24 through 331 of SEQ ID NO:21;~~

~~and culturing a recombinant host cell comprising said expression vector under conditions promoting expression of said HPR2 polypeptide.~~

22. (previously presented). The polypeptide of claim 21, wherein the polypeptide is produced by a method further comprising purifying the polypeptide.

23. (previously presented). The polypeptide of claim 21 in non-glycosylated form.

Application No. 10/715,667
Resp to OA filed June 21, 2006
Office Action dated April 28, 2006

24. (previously presented). The polypeptide of claim 21, wherein the polypeptide is produced by a method comprising culturing a recombinant host cell selected from the group consisting of mammalian cells, prokaryotic cells, and yeast cells.
25. previously presented). The polypeptide of claim 13, wherein the polypeptide is produced by a process comprising culturing a recombinant host cell under conditions promoting expression of said polypeptide.
26. (previously presented). The polypeptide of claim 25 in non-glycosylated form.
27. (previously presented). The polypeptide of claim 25, wherein the polypeptide is produced by a method comprising culturing a recombinant host cell comprising an expression vector comprising a nucleic acid encoding said polypeptide.
28. (previously presented). The polypeptide of claim 25, wherein the polypeptide is produced by a method comprising culturing a recombinant host cell selected from the group consisting of mammalian cells, prokaryotic cells, and yeast cells.